نتائج البحث - "Kollmeier, Alexa P"

1

دورية أكاديمية

Modulation of IL‐23 signaling with guselkumab in biologic‐naïve patients versus TNF inhibitor‐inadequate responders with active psoriatic arthritis

المؤلفون: Siebert, Stefan, Coates, Laura C., Schett, Georg, Raychaudhuri, Siba P., Chen, Warner, Gao, Sheng, Seridi, Loqmane, Chakravarty, Soumya D., Shawi, May, Lavie, Frederic, Sharaf, Mohamed, Zimmermann, Miriam, Kollmeier, Alexa P., Xu, Xie L., Rahman, Proton, Mease, Philip J., Deodhar, Atul

وصف الملف: text

العلاقة: https://eprints.gla.ac.uk/317165/1/317165.pdfTest; Siebert, S. et al. (2024) Modulation of IL‐23 signaling with guselkumab in biologic‐naïve patients versus TNF inhibitor‐inadequate responders with active psoriatic arthritis. Arthritis and Rheumatology , (doi:10.1002/art.42803 ) (Early Online Publication)

الإتاحة: https://doi.org/10.1002/art.42803Test
https://eprints.gla.ac.uk/317165Test/
https://eprints.gla.ac.uk/317165/1/317165.pdfTest

View record in BASE

2

دورية أكاديمية

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis

المؤلفون: Siebert, Stefan, Coates, Laura C., Schett, Georg, Raychaudhuri, Siba P., Chen, Warner, Gao, Sheng, Seridi, Loqmane, Chakravarty, Soumya D., Shawi, May, Lavie, Frederic, Sharaf, Mohamed, Zimmermann, Miriam, Kollmeier, Alexa P., Xu, Xie L., Rahman, Proton, Mease, Philip J., Deodhar, Atul

المساهمون: Janssen Research and Development

المصدر: Arthritis & Rheumatology ; volume 76, issue 6, page 894-904 ; ISSN 2326-5191 2326-5205

الإتاحة: https://doi.org/10.1002/art.42803Test

View record in BASE

3

دورية أكاديمية

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

المؤلفون: Coates, Laura C., Rahman, Proton, Mease, Philip J., Shawi, May, Rampakakis, Emmanouil, Kollmeier, Alexa P., Xu, Xie L., Chakravarty, Soumya D., McInnes, Iain B., Tam, Lai-Shan

المساهمون: Janssen Global Medical Affairs

المصدر: BMC Rheumatology ; volume 8, issue 1 ; ISSN 2520-1026

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1186/s41927-024-00375-wTest

View record in BASE

4

دورية أكاديمية

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

المؤلفون: Coates, Laura C, Gossec, Laure, Zimmermann, Miriam, Shawi, May, Rampakakis, Emmanouil, Shiff, Natalie J, Kollmeier, Alexa P, Xu, Xie L, Nash, Peter, Mease, Philip J, Helliwell, Philip S

المساهمون: Janssen Research & Development, LLC, Spring House, PA

المصدر: RMD Open ; volume 10, issue 1, page e003977 ; ISSN 2056-5933

الإتاحة: https://doi.org/10.1136/rmdopen-2023-003977Test

View record in BASE

5

دورية أكاديمية

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

المؤلفون: Ritchlin, Christopher T., Deodhar, Atul, Boehncke, Wolf‐Henning, Soriano, Enrique R., Kollmeier, Alexa P., Xu, Xie L., Zazzetti, Federico, Shawi, May, Jiang, Yusang, Sheng, Shihong, Helliwell, Philip S.

المصدر: ACR Open Rheumatology ; volume 5, issue 3, page 149-164 ; ISSN 2578-5745 2578-5745

الإتاحة: https://doi.org/10.1002/acr2.11523Test

View record in BASE

6

دورية أكاديمية

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

المؤلفون: McGonagle, Dennis, McInnes, Iain B., Deodhar, Atul, Schett, Georg, Shawi, May, Chakravarty, Soumya D., Kollmeier, Alexa P., Xu, Xie L., Sheng, Shihong, Xu, Stephen, Ritchlin, Christopher T., Rahman, Proton, Mease, Phillip J.

المساهمون: Janssen Research and Development

المصدر: ACR Open Rheumatology ; volume 5, issue 4, page 227-240 ; ISSN 2578-5745 2578-5745

الإتاحة: https://doi.org/10.1002/acr2.11537Test

View record in BASE

7

دورية أكاديمية

Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment : Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis

المؤلفون: Rahman, Proton, Boehncke, Wolf-Henning, Mease, Philip J, Gottlieb, Alice B, McInnes, Iain B, Shawi, May, Wang, Yanli, Sheng, Shihong, Kollmeier, Alexa P, Theander, Elke, Yu, Jenny, Leibowitz, Evan, Marrache, A Marilise, Coates, Laura C

المصدر: ISSN: 0315-162X ; Journal of rheumatology, vol. 50, no. 6 (2023) p. 769-780.

مصطلحات موضوعية: info:eu-repo/classification/ddc/616, Adverse effects, Biologic therapy, Guselkumab, Hepatic transaminase, Psoriatic arthritis, Safety, Humans, Arthritis, Psoriatic / drug therapy, Tumor Necrosis Factor Inhibitors / adverse effects, Antirheumatic Agents / adverse effects, Treatment Outcome, Double-Blind Method

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36642439; https://archive-ouverte.unige.ch/unige:176226Test; unige:176226

الإتاحة: https://doi.org/10.3899/jrheum.220928Test
https://archive-ouverte.unige.ch/unige:176226Test

View record in BASE

8

دورية أكاديمية

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience : Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study

المؤلفون: Ritchlin, Christopher T, Deodhar, Atul, Boehncke, Wolf-Henning, Soriano, Enrique R, Kollmeier, Alexa P, Xu, Xie L, Zazzetti, Federico, Shawi, May, Jiang, Yusang, Sheng, Shihong, Helliwell, Philip S

المصدر: ISSN: 2578-5745 ; ACR open rheumatology, vol. 5, no. 3 (2023) p. 149-164.

مصطلحات موضوعية: info:eu-repo/classification/ddc/616

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36762512; https://archive-ouverte.unige.ch/unige:176221Test; unige:176221

الإتاحة: https://doi.org/10.1002/acr2.11523Test
https://archive-ouverte.unige.ch/unige:176221Test

View record in BASE

9

دورية أكاديمية

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis

المؤلفون: Gottlieb, Alice B., McInnes, Iain B., Rahman, Proton, Kollmeier, Alexa P., Xu, Xie L., Jiang, Yusang, Sheng, Shihong, Shawi, May, Chakravarty, Soumya D., Lavie, Frederic, Mease, Philip J.

وصف الملف: text

العلاقة: https://eprints.gla.ac.uk/293489/1/293489.pdfTest; Gottlieb, A. B. et al. (2023) Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open , 9(1), e002789. (doi:10.1136/rmdopen-2022-002789 ) (PMID:36828643) (PMCID:PMC9972414)

الإتاحة: https://doi.org/10.1136/rmdopen-2022-002789Test
https://eprints.gla.ac.uk/293489Test/
https://eprints.gla.ac.uk/293489/1/293489.pdfTest

View record in BASE

10

دورية أكاديمية

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

المؤلفون: Siebert, Stefan, Sweet, Kristen M., Ritchlin, Christopher T., Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Seridi, Loqmane, Song, Qingxuan, Gao, Sheng, Chen, Warner, Miron, Michelle

المساهمون: Janssen Research and Development

المصدر: ACR Open Rheumatology ; volume 5, issue 9, page 490-498 ; ISSN 2578-5745 2578-5745

الإتاحة: https://doi.org/10.1002/acr2.11589Test

View record in BASE

تنقيح النتائج